Article Text

Download PDFPDF
Is combination chemotherapy superior to single-agent chemotherapy in second-line treatment?
  1. A. González-Martín
  1. Address correspondence and reprint requests to: Antonio González-Martín, Medical Oncology Service, University Hospital Ramón y Cajal, Ctra Colmenar Viejo Km 9100, 28034 Madrid, Spain. Email: agonzalez.hrc{at}


Treatment of relapsed ovarian carcinoma is still a matter of controversy. One important question to be solved is the potential superiority of combination chemotherapy over single-agent chemotherapy. This is a field in which a nonconclusive small number of randomized clinical trials have been conducted, and therefore, definitive conclusions are lacking. Patients with recurrent platinum-resistant disease are better treated with sequential single agent, because of higher toxicity without clear benefit usually associated with combination chemotherapy. In patients with platinum-sensitive disease, we can choose between three options: single-agent carboplatin, single-agent new drug or platinum combination-based therapy. In this paper, we will review these options and recently closed or ongoing randomized clinical trials in this setting.

  • recurrent
  • relapsed
  • epithelial ovarian carcinoma
  • second line therapy
  • combination chemotherapy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.